ARIAD SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP announces the investigation of ARIAD Pharmaceuticals, Inc. (ARIA) over the proposed sale of the company to Takeda Pharmaceutical Company Limited.

Nadeem Faruqi, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of ARIAD Pharmaceuticals, Inc. for potential breaches of fiduciary duties in connection with the sale of the company to Takeda Pharmaceutical Company Limited for approximately $5.2 billion. The company’s stockholders will only receive $24.00 in cash for each share of ARIAD’s common stock they own.

The investigation focuses on whether ARIAD’s Board of Directors breached their fiduciary duties to the company’s stockholders by failing to conduct a fair sales process and whether and by how much this proposed transaction undervalues the company to the detriment of ARIAD’s shareholders.

Faruqi & Faruqi, LLP is working together in this investigation with Juan E. Monteverde from Monteverde & Associates PC.

For more information, go to: www.faruqilaw.com/ARIA. 

(Source: PR Newswire)

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!